2-[2-(Nitrosothio)adamantan-2-yl]ethan-1-ol | 260268-08-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[2-(Nitrosothio)adamantan-2-yl]ethan-1-ol
• 英文别名: 2-(2-Nitrososulfanyl-2-adamantyl)ethanol
• CAS: 260268-08-4
• 化学式: C₁₂H₁₉NO₂S
• 分子量: 241.354
• InChiKey: TYPWBBLWMSYODI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  75
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[2-(Nitrosothio)adamantan-2-yl]ethan-1-ol 、 前列地尔 在 4-二甲氨基吡啶 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以69.5%的产率得到2-[2-(nitrosothio)adamantan-2-yl]ethyl 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]heptanoate
  参考文献：
  名称：

  Nitrostated and nitrosylated prostaglandins, compositions and methods of use

  摘要：

  本发明描述了新型亚硝酸化和/或亚硝基化前列腺素，以及包含至少一种亚硝酸化和/或亚硝基化前列腺素的新型组合物，可选择地还包括至少一种捐赠、转移或释放一氧化氮、提高内源性内皮源性舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物，和/或至少一种血管活性药物。本发明还提供了包含至少一种前列腺素和至少一种S-亚硝基硫醇化合物的新型组合物，可选择地还包括至少一种血管活性药物。前列腺素最好是前列腺素E1化合物，更好的是前列腺素E1的异前列腺素，S-亚硝基硫醇化合物最好是S-亚硝基谷胱甘肽。本发明还提供了治疗或预防男性和女性性功能障碍、增强男性和女性性反应以及治疗或预防脑血管疾病、心血管疾病、良性前列腺增生（BPH）、青光眼、消化性溃疡或引发流产的方法。本发明的化合物和/或组合物也可以以药物配套的形式提供。

  公开号：

  US07176238B1
• 作为产物：
  描述：

  2-(2-Sulfanyladamantan-2-yl)ethan-1-ol 在 亚硝酸特丁酯 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以80%的产率得到2-[2-(Nitrosothio)adamantan-2-yl]ethan-1-ol
  参考文献：
  名称：

  Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use

  摘要：

  本发明描述了新型的硝化和/或亚硝化质子泵抑制剂化合物，以及包含至少一种质子泵抑制剂化合物的新型组合物，该化合物可以选择地取代至少一个NO和/或NO2基团，并且可以选择地包含至少一种提供、转移或释放一氧化氮、诱导内源性一氧化氮或内皮源性舒张因子产生、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物，和/或至少一种非甾体抗炎药、选择性COX-2抑制剂、抗酸剂、含铋试剂、酸降解抗菌化合物及其混合物。本发明还提供了治疗和/或预防胃肠道疾病的方法；促进溃疡愈合；减少溃疡复发；改善质子泵抑制剂的胃保护性能、抗幽门螺杆菌性能或抗酸性能；减少或降低与非甾体抗炎化合物使用相关的胃肠道毒性；治疗幽门螺杆菌和病毒感染。本发明的化合物和/或组合物还可以以药用工具包的形式提供。

  公开号：

  US20040266828A1

文献信息

• Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
  申请人：——

  公开号：US20020143007A1

  公开（公告）日：2002-10-03

  The present invention describes novel nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one &agr;-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

  本发明描述了新型硝化和/或硝基化α-肾上腺素受体拮抗剂，以及包含至少一种硝化和/或硝基化α-肾上腺素受体拮抗剂的新型组合物，以及可选地包含一种或多种捐赠、转移或释放一氧化氮、提高内源性内皮衍生松弛因子水平、刺激内源性一氧化氮合成或是一氧化氮合成酶底物的化合物，和/或一种或多种血管活性药物。本发明还提供了包含至少一种α-肾上腺素受体拮抗剂和一种或多种捐赠、转移或释放一氧化氮、提高内源性内皮衍生松弛因子水平、刺激内源性一氧化氮合成或是一氧化氮合成酶底物，和/或一种或多种血管活性药物的新型组合物。本发明还提供了用于治疗或预防男性和女性的性功能障碍、增强男性和女性的性反应，以及治疗或预防良性前列腺增生、高血压、充血性心力衰竭、变异性（Printzmetal）心绞痛、青光眼、神经退行性疾病、血管痉挛性疾病、认知障碍、急迫性尿失禁或过度活跃膀胱，以及逆转麻醉状态的方法。
• [EN] NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE<br/>[FR] ANTAGONISTES NITROSES ET NITROSYLES DES RECEPTEURS ALPHA-ADRENERGIQUES, COMPOSITIONS ET METHODES D'UTILISATION
  申请人：NITROMED INC

  公开号：WO2000012075A1

  公开（公告）日：2000-03-09

  The present invention describes novel nitrosated and/or nitrosylated α-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated α-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one α-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

  本发明描述了新型的硝化和/或亚硝化α-肾上腺素受体拮抗剂，以及至少包含一种硝化和/或亚硝化α-肾上腺素受体拮抗剂的新型组合物，以及可选地，一个或多个化合物，它们捐赠、转移或释放一氧化氮，提高内皮源性松弛因子的内源水平，刺激内源性一氧化氮的合成或是一氧化氮合酶的底物，和/或一个或多个血管活性药物。本发明还提供了至少包含一种α-肾上腺素受体拮抗剂、一个或多个化合物，它们捐赠、转移或释放一氧化氮，提高内皮源性松弛因子的内源水平，刺激内源性一氧化氮的合成或是一氧化氮合酶的底物，和/或一个或多个血管活性药物的新型组合物。本发明还提供了用于治疗或预防男女性功能障碍，增强男女性反应，治疗或预防良性前列腺增生、高血压、充血性心力衰竭、变异性（普林兹金属）心绞痛、青光眼、神经退行性疾病、血管痉挛性疾病、认知障碍、压力性尿失禁或过度活动性膀胱，以及逆转麻醉状态的方法。
• Nitrosated and nitrosylated compounds, compositions and methods use
  申请人：Earl A. Richard

  公开号：US20060009431A1

  公开（公告）日：2006-01-12

  The invention describes novel nitrosated and/or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and at least one nitric oxide donor compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering at least one compound of the invention that is optionally nitrosated and/or nitrosylated, in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The compounds of the invention are preferably estradiol compounds, troglitazone compounds, tranilast compounds, retinoic acid compounds, resveratol compounds, myophenolic acid compounds, acid compounds, anthracenone compounds and trapidil compounds.

  该发明描述了该发明的新型亚硝酰化和/或亚硝基化化合物及其药学上可接受的盐，并且描述了包含至少一种该发明的亚硝酰化和/或亚硝基化化合物的新型组合物，以及可选地包含至少一种一氧化氮供体化合物和/或至少一种治疗剂的新型组合物。该发明还提供了包含至少一种该发明化合物的新型组合物，该化合物可选地亚硝酰化和/或亚硝基化，以及至少一种一氧化氮供体化合物和/或至少一种治疗剂。该发明的化合物和组合物也可以与基质结合。该发明还提供了治疗心血管疾病、抑制血液暴露于医疗设备导致的血小板聚集和粘附、治疗由异常细胞增殖引起的病理性状况；移植排斥、自身免疫、炎症、增殖、过度增殖或血管疾病；减少瘢痕组织或抑制伤口收缩，特别是通过在生理条件下给予至少一种可选地亚硝酰化和/或亚硝基化的该发明化合物与能够释放一氧化氮或在生理条件下间接传递或传递一氧化氮到靶位点的一氧化氮供体的组合物来预防和/或治疗再狭窄的预防性和/或治疗性治疗的方法。该发明的化合物首选为雌二醇化合物、曲格列酮化合物、曲安奈德化合物、视黄酸化合物、白藜芦醇化合物、肌酚酸化合物、酸化合物、蒽酮化合物和曲唑酮化合物。
• Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds
  申请人：Garvey S. David

  公开号：US20050187222A1

  公开（公告）日：2005-08-25

  The present invention describes novel nitrosated and/or nitrosylated α-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated α-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one α-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

  本发明描述了新型的硝化和/或亚硝化α-肾上腺素受体拮抗剂，以及包含至少一种硝化和/或亚硝化α-肾上腺素受体拮抗剂的新型组合物，以及可选地，一种或多种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物和/或一种或多种血管活性剂。本发明还提供了包含至少一种α-肾上腺素受体拮抗剂和一种或多种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或一种或多种血管活性剂的新型组合物。本发明还提供了用于治疗或预防男女性功能障碍、增强男女性反应、治疗或预防良性前列腺增生、高血压、充血性心力衰竭、变异性（Printzmetal）心绞痛、青光眼、神经退行性疾病、血管痉挛性疾病、认知障碍、切欲性尿失禁或膀胱过度活动，并逆转麻醉状态的方法。
• Nitrosated and nitrosylated prostaglandins, compositions and methods of use
  申请人：Garvey S. David

  公开号：US20070112067A1

  公开（公告）日：2007-05-17

  The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E 1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions.

  该发明描述了新型的硝化和/或亚硝化前列腺素，以及包含至少一种硝化和/或亚硝化前列腺素的新型组合物，可选地，包含至少一种捐赠、转移或释放一氧化氮、提高内皮源性舒张因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物，和/或至少一种血管活性药剂。该发明还提供了包含至少一种前列腺素和至少一种S-亚硝基硫醇化合物的新型组合物，可选地，包含至少一种血管活性药剂。前列腺素最好是一种前列腺素E1化合物，更好的是前列腺素E1的一种丙型前列腺素，而S-亚硝基硫醇化合物最好是S-亚硝基谷胱甘肽。该发明还提供了治疗或预防男女性功能障碍、增强男女性反应、治疗或预防脑血管疾病、心血管疾病、良性前列腺增生症、青光眼、消化性溃疡或引产的方法。